Drug Type CRISPR/Cas9  | 
Synonyms-  | 
Target  | 
Action inhibitors, modulators  | 
Mechanism PTBP1 inhibitors(polypyrimidine tract binding protein 1 inhibitors), ROCK modulators(Rho-associated kinases modulators)  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Parkinson Disease | Preclinical | China   | 23 Apr 2024 | 





